Advertisement
YOU ARE HERE: LAT HomeCollectionsRaptiva Drug
IN THE NEWS

Raptiva Drug

FEATURED ARTICLES
BUSINESS
July 21, 2005 | From Bloomberg News
Genentech Inc. warned doctors of a potential anemia risk for users of its Raptiva psoriasis drug and updated earlier cautions about infections and a bleeding disorder. Two people had a form of anemia stemming from premature destruction of red blood cells during studies conducted to win Raptiva's U.S. approval in 2003, the South San Francisco-based company said in a letter to doctors posted on the Food and Drug Administration's website.
ARTICLES BY DATE
BUSINESS
July 21, 2005 | From Bloomberg News
Genentech Inc. warned doctors of a potential anemia risk for users of its Raptiva psoriasis drug and updated earlier cautions about infections and a bleeding disorder. Two people had a form of anemia stemming from premature destruction of red blood cells during studies conducted to win Raptiva's U.S. approval in 2003, the South San Francisco-based company said in a letter to doctors posted on the Food and Drug Administration's website.
Advertisement
BUSINESS
September 10, 2003 | Denise Gellene, Times Staff Writer
A medical advisory panel Tuesday recommended Food and Drug Administration approval of Raptiva, bringing Genentech Inc. closer to entering the coveted market for psoriasis drugs. The expert committee voted 11 to 0 to recommend Raptiva for moderate to severe psoriasis, a chronic skin disease that affects as many as 4 million people in the U.S. The FDA isn't required to follow its panel's advice, but it usually does. The committee acted after the markets closed.
BUSINESS
September 10, 2003 | Denise Gellene, Times Staff Writer
A medical advisory panel Tuesday recommended Food and Drug Administration approval of Raptiva, bringing Genentech Inc. closer to entering the coveted market for psoriasis drugs. The expert committee voted 11 to 0 to recommend Raptiva for moderate to severe psoriasis, a chronic skin disease that affects as many as 4 million people in the U.S. The FDA isn't required to follow its panel's advice, but it usually does. The committee acted after the markets closed.
BUSINESS
March 23, 2004 | From Bloomberg News
Genentech Inc. and Xoma Ltd. said Raptiva, their drug for the skin disorder psoriasis, failed in a study to ease symptoms of a related form of arthritis. Shares of both companies fell, with Xoma down 13%. There was no significant difference in joint pain between psoriatic arthritis patients taking Raptiva and those receiving a placebo, the two California companies said. The medicine did improve psoriasis symptoms. The results probably shut off an avenue for future Raptiva sales growth.
BUSINESS
April 8, 2004 | Denise Gellene, Times Staff Writer
Genentech Inc. continued its hot streak Wednesday as strong first-quarter sales offset the cost of launching its newest cancer drug, Avastin. Net income increased 17% to $176.6 million, or 33 cents a share, from $151 million, or 30 cents, in last year's first quarter. Excluding special charges related to litigation and other items, profit was $207.6 million, or 38 cents, the company said.
Los Angeles Times Articles
|